Alert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 3:00 pm through Tuesday, March 03, 9:00 pm (PST), 2026
Ordering can continue through fax and phone.
Contact us
Alert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 3:00 pm through Tuesday, March 03, 9:00 pm (PST), 2026
Ordering can continue through fax and phone.
Contact usAlert : The site is undergoing maintenance. Some functionality including sign-in may be impacted
Saturday, February 21, 3:00 pm through Tuesday, March 03, 9:00 pm (PST), 2026
.Ordering can continue through fax and phone.
Contact usThis page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}. You’re currently on the {originCountryName} site. Do you want to switch to a different country site?
The authors of this article (Hasegawa, et.al, Nat.Immun 2019) have studied the formation of osteoclasts, which play a crucial role in arthritic bone erosion. They have developed an original protocol to isolate the inflamed synovium from arthritic mice and have identified specific macrophages called arthritis-associated osteoclastogenic macrophages (AtoMs) as osteoclast precursors in arthritic joints. AtoMs are a subset distinct from the osteoclast precursors in bone marrow. Transcription profiling using RNA sequencing experiments enabled them to establish that the transcription factor FoxM1 is a key regulator responsible for the differentiation of AtoM macrophages into osteoclasts in the synovium. Single-cell mRNA sequencing experiments performed using the BD Rhapsody™ system and t-distributed stochastic neighbourhood embedding (t-SNE) enabled the clustering of cells based on gene expression. From this, it was possible to identify clusters in which osteoclast-related genes were highly expressed. From these and other experiments, the authors could establish that rheumatoid arthritis synovial AtoM macrophages had high osteoclastogenic potential and FoxM1 constitutes a potential target for treatment.
BD, the BD Logo and BD Rhapsody™ are trademarks of Becton, Dickinson and Company or its affiliates © 2020 BD. All rights reserved.
Products For Research Use Only. Not for use in diagnostic or therapeutic procedures.